Amneal Pharmaceuticals Inc. (NYSE:AMRX) saw an upside of 0.81% to close Friday at $3.73 after adding $0.03 on the day. The 5-day average trading volume is 1,054,220 shares of the company’s common stock. It has gained $4.11 in the past week and touched a new high 1 time within the past 5 days. An average of 1,210,570 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,201,950.
AMRX’s 1-month performance is 5.07% or $0.49 on its low of $2.99 reached on 07/28/23. The company’s shares have touched a 52-week low of $1.24 and high of $4.74, with the stock’s rally to the 52-week high happening on 08/07/23. YTD, AMRX has achieved 87.44% or $1.74 and has reached a new high 24 times. However, the current price is down -21.31% from the 52-week high price.
Insider Transactions
AMRX stock investors last saw insider trading activity on Aug 11.BOYER ANDREW S (Executive Vice President) most recently sold 29,302 shares at $4.13 per share on Aug 11. This transaction cost the insider $120,921. Former 10% Owner, TPG GP A, LLC, sold 3,884,600 shares at a price of $2.34 on Dec 12.
Valuation Metrics
AMRX stock has a beta of 1.28. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 0.49 while the price-to-book (PB) in the most recent quarter is 1.80, with the price to cash flow ratio at 9.93.
Amneal Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 1.10, with the current ratio over the same period at 1.80. As well, the company’s long term debt to equity for the quarter ending June 29 was 8.33, while the total debt to equity was 8.81. In terms of profitability, the gross margin trailing 12 months is 35.20%. The trailing 12-month EBITDA margin is 19.92% while for the period ending June 29, Amneal Pharmaceuticals Inc.’s operating margin was 8.40%. The firm’s gross profit as reported stood at $784.71 million against revenue of $2.21 billion.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 1113.51% to $11.92 million, while revenue of -$6.94 million was 158.22% off the previous quarter. Analysts expected AMRX to announce $0.11 per share in earnings in its latest quarter, but it posted $0.19, representing a 72.70% surprise. EBITDA for the quarter stood at more than $139.66 million. AMRX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 3.55 billion, with total debt at $2.86 billion. Shareholders hold equity totaling $306.31 million.
Let’s look briefly at Amneal Pharmaceuticals Inc. (AMRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 49.68% to suggest the stock is trending Neutral, with historical volatility in this time period at 134.53%.
The stock’s 5-day moving average is $3.79, reflecting a -6.05% or -$0.24 change from its current price. AMRX is currently trading +10.68% above its 20-day SMA, +189.15% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +51.63% and SMA200 by+69.55%.
Stochastic %K and %D was 38.01% and 42.94% and the average true range (ATR) pointed at 0.26. The RSI (14) points at 54.19%, while the 14-day stochastic is at 38.79% with the period’s ATR at 0.25. The stock’s 9-day MACD Oscillator is pointing at -0.29 and -0.18 on the 14-day charts.
Analyst Ratings
Analysts offering their rating for AMRX stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate AMRX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 3 have offered a “buy” rating.
What is AMRX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $5.00 and a high of $6.00, with their median price target at $5.00. Looking at these predictions, the average price target given by analysts is for Amneal Pharmaceuticals Inc. (AMRX) stock is $5.25.
